source
- Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 dataBiogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…
- BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphomaBeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma. The approval is based on…